GlaxoSmithKline

GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the following segments: Pharmaceuticals; Pharmaceuticals R&D; Vaccines and Consumer Healthcare. The Pharmaceuticals segment focuses on developing medicines in respiratory and infectious diseases, oncology, and immuno-inflammation. The Pharmaceuticals R&D segment focuses on science related to the immune system, the use of human genetics and advanced technologies, and is driven by the multiplier effect of Science x Technology x Culture. The Vaccines segment produces pediatric and adult vaccines to prevent a range of infectious diseases including, hepatitis A and B, diphtheria, tetanus and whooping cough, measles, mumps and rubella, polio, typhoid, influenza, and bacterial meningitis. The Consumer Healthcare segment develops and markets brands in the oral health, pain relief, respiratory, nutrition and gastro intestinal, and skin health categories. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.

GlaxoSmithKline (GSK) has told around 2,500 staff in Britain to turn off a Covid-19 contact-tracing app while at work.

British pharma giant GlaxoSmithKline tells staff to turn off contact-tracing app while at work

Vir Biotechnology

Vir Biotechnology Inc (NASDAQ: VIR) shares were rallying Tuesday after the company provided an update on its partnered COVID-19 treatment program. Vir's COVID-19 Antibody Update: Vir said it is advancing VIR-7831 — a fully human anti-SARS-CoV-2 monoclonal antibody it is developing along with GlaxoSmithKline plc (NYSE: GSK) — into a global Phase 3 trial dubbed COMET-ICE.

Vir Biotech, GlaxoSmithKline Advance COVID-19 Antibody Treatment Into Global, Late-Stage Trial

The global trial of the experimental antibody therapy will expand following promising safety results in early trial participants.

Antibody Therapy From GSK, Vir Goes To Phase 3 Trials

Vir Biotechnology and U.K.-based partner GlaxoSmithKline said they are expanding Phase 3, or final-phase, clinical trials for a possible Covid-19 antibody treatment. VIR stock jumped.

Vir Biotechnology, GlaxoSmithKline Expanding Phase 3 Trials For Covid-19 Treatment

Shares of Vir Biotechnology Inc. gained 5.3% in trading on Tuesday after the company said it is expanding the Phase 3 clinical trial for an experimental COVID-19 treatment.

Vir's stock rises as COVID-19 drug moves to late-study clinical trial

Vir Biotechnology Inc. (NASDAQ: VIR) shares jumped on Tuesday after the firm announced, in conjunction with GlaxoSmithKline PLC (NYSE: GSK), that they would be expanding their late-stage COVID-19 study.

Vir Biotechnology Expands Its Late-Stage COVID-19 Study

SAN FRANCISCO and LONDON, Oct. 06, 2020 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) and GlaxoSmithKline plc (LSE/NYSE: GSK) today announced the global expansion to Phase 3 of the COMET-ICE (COVID-19 Monoclonal antibody Efficacy Trial - Intent to Care Early) study evaluating VIR-7831 for the early treatment of COVID-19 in patients who are at high risk of hospitalization. VIR-7831 (also known as GSK4182136) is a fully human anti-SARS-CoV-2 (Severe Acute Respiratory Syndrome coronavirus-2) monoclonal antibody that was selected based on its potential to neutralize the virus, kill infected cells, provide a high barrier to resistance, and achieve high concentrations in the lungs (one of the major sites of infection). Following a positive assessment of unblinded safety data from the lead-in portion of the trial by an Independent Data Monitoring Committee on September 30, 2020, the COMET-ICE registrational study will now expand globally to additional sites in North America, South America and Europe.

Vir Biotechnology and GSK announce global expansion to Phase 3 of COMET-ICE study evaluating VIR-7831 for the treatment of COVID-19

The developers of a potential COVID-19 vaccine have moved trials to a third phase, hailing "rapid achievement" to date.

'Rapid achievement' allows vaccine trial to move to next phase

AstraZeneca

NVIDIA

Nvidia Corporation (NASDAQ: NVDA) said Monday it is working to build the United Kingdom’s most powerful supercomputer, which it will provide to healthcare researchers working on COVID-19. What Happened: The “Cambridge-1” is expected to come online by the end of 2020 and is expected to be ranked 29 among the TOP500 list of the world’s most powerful supercomputers, Nvidia said in a statement.

COVID-19 Vaccine Makers AstraZeneca, GSK To Get First Access To Nvidia's 'Cambridge-1' Supercomputer

Nvidia Corp. (NASDAQ: NVDA) shares jumped on Monday amid a flurry of updates from the semiconductor firm.

How Nvidia Is Fighting Disease With AI

Nvidia Corp. shares NVDA, +3.86% are up 3% in Monday trading after the company said it would partner with GlaxoSmithKline PLC GSK, +0.85% to use computing and artificial intelligence for drug discovery.

Nvidia announces partnership with GSK focused on drug discovery

Teva Pharmaceutical

The U.S. Federal Circuit Court of Appeals said on Friday that Teva Pharmaceutical Industries Ltd (TLV: TEVA) will compensate GlaxoSmithKline plc (LON: GSK) with a payment of £182.09 million – a verdict that was originally given by a jury in 2017. At £704.50 per share, Teva Pharmaceutical is now roughly 8% down year to date in the stock market.

U.S. federal appeals court reinstates GSK’s £182 million ruling against Teva Pharmaceutical

Pfizer

One of these big pharma stocks appears to have an advantage.

Better Buy: GlaxoSmithKline vs. Pfizer

Glaxo's (GSK) Nucala becomes the first and only targeted biologic treatment to be approved for hypereosinophilic syndrome (HES), a rare disease caused by eosinophilic inflammation.

Glaxo Gets FDA Nod for Nucala for Hypereosinophilic Syndrome

LONDON--(BUSINESS WIRE)--GlaxoSmithKline plc (GSK) (LSE/NYSE: GSK) today announced the US Food and Drug Administration (FDA) has approved Nucala (mepolizumab) for the treatment of adult and pediatric patients aged 12 years and older with Hypereosinophilic Syndrome (HES) for ≥ six months without an identifiable non-hematologic secondary cause. The approval makes Nucala the first and only targeted biologic treatment to be approved for patients with this eosinophil-driven disease in the US. Dr Hal

FDA Approves Nucala as the First and Only Biologic Treatment for Hypereosinophilic Syndrome (HES)

Bayer AG

Biogen

Bank of New York Mellon

Bristol-Myers

British American Tobacco

Cerner

Imperial Brands PLC

Intel

Altria

Merck

Philip Morris

Roche Holding AG

Wide-Moat Stocks On Sale - The October 2020 Heat Map

Sanofi

Sanofi's (SNY) recombinant protein-based technology is being combined with Glaxo's pandemic adjuvant technology to develop an adjuvanted COVID-19 vaccine.

Sanofi/Glaxo to Supply 70M Coronavirus Vaccine Doses in Canada

Sanofi SNY, -2.14% SAN, -1.30% and GlaxoSmithKline PLC GSK, -1.23% GSK, -0.53% announced Tuesday that the companies have signed agreements with Canada to supply up to 72 million doses of their COVID-19 vaccine, starting in 2021.

Sanofi, GlaxoSmithKline signs deal with Canada to deliver 72 million doses of potential COVID-19 vaccine

Sanofi and GSK sign agreements with the Government of Canada to supply up to 72 million doses of adjuvanted COVID-19 vaccine

Anthem

BHP Billiton

Morgan Stanley

Rio Tinto plc Sponsored

Royal Bank of Canada

According to the GuruFocus All-in-One Screener as of Sept. 21, the following guru-held companies have high dividend yields and are trading with low price-earnings ratios.

6 Cheap Stocks Paying a High Dividend Yield

The CHMP's favorable response recommends the regulatory nod for GlaxoSmithKline's (GSK) Zejula as the first-line maintenance treatment of ovarian cancer patients regardless of the biomarker status.

Glaxo's Zejula Gets Positive CHMP View for First-Line Setting

Sanofi (SNY) recombinant protein-based technology is being combined with Glaxo's (GSK) pandemic adjuvant technology to develop an adjuvanted COVID-19 vaccine.

Sanofi/Glaxo to Supply 300M Coronavirus Vaccine Doses in EU

GlaxoSmithKline (GSK) closed at $39.26 in the latest trading session, marking a -0.53% move from the prior day.

GlaxoSmithKline (GSK) Stock Moves -0.53%: What You Should Know

GlaxoSmithKline and Sanofi stock are rallying in early trading on Friday thanks to news they would supply the EU 300 million vaccine doses.
The post GlaxoSmithKline and Sanofi Stock Rally on EU Vaccine Deal appeared first on InvestorPlace.

GlaxoSmithKline and Sanofi Stock Rally on EU Vaccine Deal

NEW YORK, Sept. 16, 2020 /PRNewswire/ -- The Lupus Research Alliance welcomes positive BLISS-LN Phase 3 data published in this week's New England Journal of Medicine, demonstrating that GSK's drug BenlystaR (belimumab) significantly improved kidney function in adults with lupus nephritis,.

LRA Applauds GSK on Positive Phase 3 Study of Benlysta® for Lupus Nephritis

News for GlaxoSmithKline Stock (GSK)